title: Reply to Araki et al.
authors.affiliation: Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: alipton@hmc.psu.edu.
authors.forename: Allan
authors.initials: A
authors.lastname: Lipton
authors.affiliation: Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
authors.forename: Karim
authors.initials: K
authors.lastname: Fizazi
authors.affiliation: University of Arizona, Arizona Cancer Center, Tucson, AZ, USA.
authors.forename: Alison T
authors.initials: AT
authors.lastname: Stopeck
authors.affiliation: Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA, USA.
authors.forename: David H
authors.initials: DH
authors.lastname: Henry
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Ada H
authors.initials: AH
authors.lastname: Braun
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles